Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 36

1.

Monobodies and other synthetic binding proteins for expanding protein science.

Sha F, Salzman G, Gupta A, Koide S.

Protein Sci. 2017 May;26(5):910-924. doi: 10.1002/pro.3148. Epub 2017 Mar 24. Review.

2.

A Gradient of Sitewise Diversity Promotes Evolutionary Fitness for Binder Discovery in a Three-Helix Bundle Protein Scaffold.

Woldring DR, Holec PV, Stern LA, Du Y, Hackel BJ.

Biochemistry. 2017 Mar 21;56(11):1656-1671. doi: 10.1021/acs.biochem.6b01142. Epub 2017 Mar 9.

PMID:
28248518
3.

A Conjugate Based on Anti-HER2 Diaffibody and Auristatin E Targets HER2-Positive Cancer Cells.

Serwotka-Suszczak AM, Sochaj-Gregorczyk AM, Pieczykolan J, Krowarsch D, Jelen F, Otlewski J.

Int J Mol Sci. 2017 Feb 14;18(2). pii: E401. doi: 10.3390/ijms18020401.

4.

Native and engineered tropism of vectors derived from a rare species D adenovirus serotype 43.

Belousova N, Mikheeva G, Xiong C, Stagg LJ, Gagea M, Fox PS, Bassett RL, Ladbury JE, Braun MB, Stehle T, Li C, Krasnykh V.

Oncotarget. 2016 Aug 16;7(33):53414-53429. doi: 10.18632/oncotarget.10800.

5.

Optical imaging probes in oncology.

Martelli C, Lo Dico A, Diceglie C, Lucignani G, Ottobrini L.

Oncotarget. 2016 Jul 26;7(30):48753-48787. doi: 10.18632/oncotarget.9066. Review.

6.

Programmable polyproteams built using twin peptide superglues.

Veggiani G, Nakamura T, Brenner MD, Gayet RV, Yan J, Robinson CV, Howarth M.

Proc Natl Acad Sci U S A. 2016 Feb 2;113(5):1202-7. doi: 10.1073/pnas.1519214113. Epub 2016 Jan 19.

7.

Structure-based Design of Peptides with High Affinity and Specificity to HER2 Positive Tumors.

Geng L, Wang Z, Yang X, Li D, Lian W, Xiang Z, Wang W, Bu X, Lai W, Hu Z, Fang Q.

Theranostics. 2015 Aug 1;5(10):1154-65. doi: 10.7150/thno.12398. eCollection 2015.

8.

Small sized EGFR1 and HER2 specific bifunctional antibody for targeted cancer therapy.

Ding L, Tian C, Feng S, Fida G, Zhang C, Ma Y, Ai G, Achilefu S, Gu Y.

Theranostics. 2015 Jan 21;5(4):378-98. doi: 10.7150/thno.10084. eCollection 2015.

9.

Artificial affinity proteins as ligands of immunoglobulins.

Mouratou B, BĂ©har G, Pecorari F.

Biomolecules. 2015 Jan 30;5(1):60-75. doi: 10.3390/biom5010060. Review.

10.

SpyAvidin hubs enable precise and ultrastable orthogonal nanoassembly.

Fairhead M, Veggiani G, Lever M, Yan J, Mesner D, Robinson CV, Dushek O, van der Merwe PA, Howarth M.

J Am Chem Soc. 2014 Sep 3;136(35):12355-63. doi: 10.1021/ja505584f. Epub 2014 Aug 21.

11.

Molecular imaging of EGFR/HER2 cancer biomarkers by protein MRI contrast agents.

Qiao J, Xue S, Pu F, White N, Jiang J, Liu ZR, Yang JJ.

J Biol Inorg Chem. 2014 Feb;19(2):259-70. doi: 10.1007/s00775-013-1076-3. Epub 2013 Dec 24. Review.

12.

Antibody-based imaging of HER-2: moving into the clinic.

Wang RE, Zhang Y, Tian L, Cai W, Cai J.

Curr Mol Med. 2013 Dec;13(10):1523-37. Review.

13.

Targeting HER2-positive cancer cells with receptor-redirected anthrax protective antigen.

McCluskey AJ, Olive AJ, Starnbach MN, Collier RJ.

Mol Oncol. 2013 Jun;7(3):440-51. doi: 10.1016/j.molonc.2012.12.003. Epub 2012 Dec 19.

14.

A systematic investigation of differential effects of cell culture substrates on the extent of artifacts in single-molecule tracking.

Zanetti-Domingues LC, Martin-Fernandez ML, Needham SR, Rolfe DJ, Clarke DT.

PLoS One. 2012;7(9):e45655. doi: 10.1371/journal.pone.0045655. Epub 2012 Sep 25.

15.

Cysteine-terminated B-domain of Staphylococcus aureus protein A as a scaffold for targeting GABA(A) receptors.

Qtaishat NM, Gussin HA, Pepperberg DR.

Anal Biochem. 2013 Jan 1;432(1):49-57. doi: 10.1016/j.ab.2012.08.031. Epub 2012 Sep 19.

16.

Pharmacokinetics of engineered human monomeric and dimeric CH2 domains.

Gehlsen K, Gong R, Bramhill D, Wiersma D, Kirkpatrick S, Wang Y, Feng Y, Dimitrov DS.

MAbs. 2012 Jul-Aug;4(4):466-74. doi: 10.4161/mabs.20652. Epub 2012 Jul 1.

17.

PET of EGFR expression with an 18F-labeled affibody molecule.

Miao Z, Ren G, Liu H, Qi S, Wu S, Cheng Z.

J Nucl Med. 2012 Jul;53(7):1110-8. doi: 10.2967/jnumed.111.100842. Epub 2012 Jun 11.

18.

Structure prediction and validation of an affibody engineered for cell-specific nucleic acid targeting.

Gopal V, Guruprasad K.

Syst Synth Biol. 2010 Dec;4(4):293-7. doi: 10.1007/s11693-011-9074-7. Epub 2011 Feb 17.

19.

In vitro and in vivo assessment of targeting lipid-based nanoparticles to the epidermal growth factor-receptor (EGFR) using a novel Heptameric ZEGFR domain.

Benhabbour SR, Luft JC, Kim D, Jain A, Wadhwa S, Parrott MC, Liu R, DeSimone JM, Mumper RJ.

J Control Release. 2012 Feb 28;158(1):63-71. doi: 10.1016/j.jconrel.2011.10.013. Epub 2011 Oct 20.

20.

A transductionally retargeted adenoviral vector for virotherapy of Her2/neu-expressing prostate cancer.

Magnusson MK, Kraaij R, Leadley RM, De Ridder CM, van Weerden WM, Van Schie KA, Van der Kroeg M, Hoeben RC, Maitland NJ, Lindholm L.

Hum Gene Ther. 2012 Jan;23(1):70-82. doi: 10.1089/hum.2011.016. Epub 2011 Oct 12.

Supplemental Content

Support Center